{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:11:02Z","timestamp":1792001462243,"version":"4.4.0"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T00:00:00Z","timestamp":1555459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA025368"],"award-info":[{"award-number":["AA025368"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA026949"],"award-info":[{"award-number":["AA026949"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA026675"],"award-info":[{"award-number":["AA026675"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00407","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T00:35:12Z","timestamp":1555461312000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":99,"title":["A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists"],"prefix":"10.3389","volume":"10","author":[{"given":"Kendall L.","family":"Mores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Cummins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Cassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"van Rijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior.","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"18488","DOI":"10.1073\/pnas.1104807108","article-title":"Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.","volume":"108","author":"Allen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B3","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1177\/0269881116689257","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.","volume":"31","author":"Altarifi","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1124\/jpet.106.101998","article-title":"Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.","volume":"318","author":"Ansonoff","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2018.08.002","article-title":"The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats.","volume":"192","author":"Austin Zamarripa","year":"2018","journal-title":"Drug Alcohol. Depend."},{"key":"B6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1098\/rspb.1983.0093","article-title":"Operational models of pharmacological agonism.","volume":"220","author":"Black","year":"1983","journal-title":"Proc. R. Soc. Lond. B. Biol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/35047086","article-title":"[mu]-Opioid receptor desensitization by [beta]-arrestin-2 determines morphine tolerance but not dependence.","volume":"408","author":"Bohn","year":"2000","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking beta-arrestin 2.","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/j.1532-2149.2011.00022.x","article-title":"Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes.","volume":"16","author":"Brissett","year":"2012","journal-title":"Eur. J. Pain"},{"key":"B10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00213-010-1806-y","article-title":"Kinase cascades and ligand-directed signaling at the kappa opioid receptor.","volume":"210","author":"Bruchas","year":"2010","journal-title":"Psychopharmacology (Berl.)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11614","DOI":"10.1523\/jneurosci.3769-07.2007","article-title":"Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria.","volume":"27","author":"Bruchas","year":"2007","journal-title":"J. Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"18081","DOI":"10.1074\/jbc.m513640200","article-title":"Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes.","volume":"281","author":"Bruchas","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.tips.2016.01.001","article-title":"New technologies for elucidating opioid receptor function.","volume":"37","author":"Bruchas","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1124\/jpet.114.220293","article-title":"Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways.","volume":"352","author":"Brust","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.","author":"Brust","year":"2016","journal-title":"Sci. Signal."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/s0040-4020(01)97243-6","article-title":"Isolement et analyse structurale du collybolide, nouveau sesquiterpene extrait de collybia maculata alb. et sch. ex fries (basidomycetes).","volume":"30","author":"Bui","year":"1974","journal-title":"Tetrahedron"},{"key":"B17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tins.2012.05.005","article-title":"kappa-opioid receptor\/dynorphin system: genetic and pharmacotherapeutic implications for addiction.","volume":"35","author":"Butelman","year":"2012","journal-title":"Trends Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1124\/jpet.105.092304","article-title":"Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.","volume":"316","author":"Carlezon","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/npp.2010.137","article-title":"The therapeutic potential of kappa-opioids for treatment of pain and addiction.","volume":"36","author":"Chavkin","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/npp.2015.258","article-title":"Dynorphin, dysphoria, and dependence: the stress of addiction.","volume":"41","author":"Chavkin","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"B21","doi-asserted-by":"crossref","first-page":"55.e15","DOI":"10.1016\/j.cell.2017.12.011","article-title":"Structure of the nanobody-stabilized active state of the kappa opioid receptor.","volume":"172","author":"Che","year":"2018","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1021\/jm4010829","article-title":"Structure-activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan- 9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.","volume":"56","author":"Chen","year":"2013","journal-title":"J. Med. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bph.13374","article-title":"Beta-arrestin 2 dependence of delta opioid receptor agonists is correlated with alcohol intake.","volume":"173","author":"Chiang","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"B24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.","volume":"10","author":"Chou","year":"2009","journal-title":"J. Pain"},{"key":"B25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1126\/science.aap8586","article-title":"An amygdalar neural ensemble that encodes the unpleasantness of pain.","volume":"363","author":"Corder","year":"2019","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-3-662-44605-8_16","article-title":"Targeting itch with ligands selective for kappa opioid receptors.","volume":"226","author":"Cowan","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1016\/j.celrep.2016.02.069","article-title":"Dynorphin controls the gain of an amygdalar anxiety circuit.","volume":"14","author":"Crowley","year":"2016","journal-title":"Cell Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1556\/2054.01.2017.009","article-title":"Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning.","volume":"1","author":"Davis","year":"2017","journal-title":"J. Psychedelic Stud."},{"key":"B29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/ijnp\/pyy034","article-title":"Structurally related kappa opioid receptor agonists with substantial differential signaling bias: neuroendocrine and behavioral effects in C57BL6 mice.","volume":"21","author":"Dunn","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B30","first-page":"413","article-title":"Kappa opioids in rhesus monkeys. Diuresis, I., sedation, analgesia and discriminative stimulus effects.","volume":"242","author":"Dykstra","year":"1987","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/s0024-3205(99)00417-8","article-title":"Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist.","volume":"65","author":"Endoh","year":"1999","journal-title":"Life Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.1021\/acs.jmedchem.7b00981","article-title":"Highly potent and selective new diphenethylamines interacting with the kappa-opioid receptor: synthesis, pharmacology, and structure-activity relationships.","volume":"60","author":"Erli","year":"2017","journal-title":"J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1021\/cn200128x","article-title":"Discovery of small molecule kappa opioid receptor agonist and antagonist chemotypes through a HTS and hit refinement strategy.","volume":"3","author":"Frankowski","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1021\/cn200128x","article-title":"\u201c4 opioid kappa receptor selective agonist TRK-820 (Nalfurafine Hydrochloride ),\u201d in Pharmacology","author":"Fujij","year":"2012"},{"key":"B35","doi-asserted-by":"publisher","first-page":"8024","DOI":"10.1523\/jneurosci.17-20-08024.1997","article-title":"Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain.","volume":"17","author":"Gold","year":"1997","journal-title":"J. Neurosci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1016\/j.bmcl.2016.08.031","article-title":"Structural determinants of diphenethylamines for interaction with the kappa opioid receptor: synthesis, pharmacology and molecular modeling studies.","volume":"26","author":"Guerrieri","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B37","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1073\/pnas.1521825113","article-title":"Collybolide is a novel biased agonist of kappa-opioid receptors with potent antipruritic activity.","volume":"113","author":"Gupta","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1021\/jm048963m","article-title":"Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.","volume":"48","author":"Harding","year":"2005","journal-title":"J. Med. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1111\/bph.14224","article-title":"The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception.","volume":"175","author":"Hill","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aar4309","article-title":"G protein signaling-biased agonism at the kappa-opioid receptor is maintained in striatal neurons.","author":"Ho","year":"2018","journal-title":"Sci. Signal."},{"key":"B41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuroscience.2009.06.016","article-title":"Nalfurafine prevents 5\u2032-guanidinonaltrindole- and compound 48\/80-induced spinal c-fos expression and attenuates 5\u2032-guanidinonaltrindole-elicited scratching behavior in mice.","volume":"163","author":"Inan","year":"2009","journal-title":"Neuroscience"},{"key":"B42","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.neuron.2014.02.046","article-title":"Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord.","volume":"82","author":"Kardon","year":"2014","journal-title":"Neuron"},{"key":"B43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.irn.2017.08.001","article-title":"Dynorphin\/kappa opioid receptor signaling in preclinical models of alcohol, drug, and food addiction.","volume":"136","author":"Karkhanis","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/mol.115.099770","article-title":"The effective application of biased signaling to new drug discovery.","volume":"88","author":"Kenakin","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: detection, quantification and therapeutic impact.","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"B46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1021\/cn200111m","article-title":"A simple method for quantifying functional selectivity and agonist bias.","volume":"3","author":"Kenakin","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.biopsych.2013.03.014","article-title":"The one-two punch of alcoholism: role of central amygdala dynorphins\/kappa-opioid receptors.","volume":"75","author":"Kissler","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.03.014","article-title":"Kappa opioid receptor agonist mesyl Sal B attenuates behavioral sensitization to cocaine with fewer aversive side-effects than salvinorin A in Rodents. Molecules","author":"Kivell","year":"2018"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects.","author":"Kliewer","year":"2019","journal-title":"Nat. Commun."},{"key":"B50","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.biopsych.2011.03.017","article-title":"Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats.","volume":"70","author":"Knoll","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nsmb.3014","article-title":"PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome.","volume":"22","author":"Kroeze","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol. Dial. Trans."},{"key":"B53","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1523\/JNEUROSCI.4458-07.2008","article-title":"The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.","volume":"28","author":"Land","year":"2008","journal-title":"J. Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"19168","DOI":"10.1073\/pnas.0910705106","article-title":"Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking.","volume":"106","author":"Land","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B55","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","article-title":"Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in kappa opioid aversion.","volume":"44","author":"Liu","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4927","article-title":"In vivo brain GPCR signaling elucidated by phosphoproteomics.","volume":"360","author":"Liu","year":"2018","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1021\/acschemneuro.5b00092","article-title":"Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1\/2 phosphorylation while preserving G protein over betaarrestin2 signaling bias.","volume":"6","author":"Lovell","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/mol.115.099630","article-title":"Fulfilling the promise of \u201cbiased\u201d","volume":"88","author":"Luttrell","year":"2015","journal-title":"G protein-coupled receptor agonism."},{"key":"B59","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.neuropharm.2015.08.032","article-title":"Noribogaine is a G-protein biased kappa-opioid receptor agonist.","volume":"99","author":"Maillet","year":"2015","journal-title":"Neuropharmacology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/02791072.2018.1447175","article-title":"Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine.","volume":"50","author":"Malcolm","year":"2018","journal-title":"J. Psychoact. Drugs"},{"key":"B61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects.","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1177\/0269881116641331","article-title":"Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.","volume":"30","author":"Mash","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00529","article-title":"Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes.","volume":"9","author":"Mash","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pbb.2005.12.011","article-title":"Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.","volume":"83","author":"McCurdy","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2005.12.011","article-title":"Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid mu-opioid receptor desensitization. Sci. Signal.","author":"Miess","year":"2018"},{"key":"B66","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.neuropharm.2015.08.027","article-title":"Investigation of the role of betaarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.","volume":"99","author":"Morgenweck","year":"2015","journal-title":"Neuropharmacology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00213-002-1028-z","article-title":"Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.","volume":"161","author":"Mori","year":"2002","journal-title":"Psychopharmacology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1248\/cpb.46.366","article-title":"Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan.","volume":"46","author":"Nagase","year":"1998","journal-title":"Chem. Pharm. Bull."},{"key":"B69","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pain.2008.12.006","article-title":"Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain.","volume":"141","author":"Obara","year":"2009","journal-title":"Pain"},{"key":"B70","doi-asserted-by":"publisher","first-page":"11852","DOI":"10.1073\/pnas.1510117112","article-title":"NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor.","volume":"112","author":"O\u2019Connor","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B71","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors.","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin 2 knockout mice.","volume":"314","author":"Raehal","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1523\/jneurosci.19-06-02016.1999","article-title":"Cloning and characterization of RGS9-2: a striatal-enriched alternatively spliced product of the RGS9 gene.","volume":"19","author":"Rahman","year":"1999","journal-title":"J. Neurosci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1124\/mol.111.072801","article-title":"Quantifying ligand bias at seven-transmembrane receptors.","volume":"80","author":"Rajagopal","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"27050","DOI":"10.1074\/jbc.C112.387332","article-title":"6\u2032-Guanidinonaltrindole (6\u2032-GNTI) is a G protein-biased kappa-opioid receptor agonist that inhibits arrestin recruitment.","volume":"287","author":"Rives","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00112","article-title":"Critical ROLE for Gi\/o-protein activity in the dorsal striatum in the reduction of voluntary alcohol intake in C57Bl\/6 Mice.","volume":"9","author":"Robins","year":"2018","journal-title":"Front. Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.","volume":"99","author":"Roth","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1111\/bph.13212","article-title":"Salvinorin A analogues PR-37 and PR-38 attenuate compound 48\/80-induced itch responses in mice.","volume":"172","author":"Salaga","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cell. Signal."},{"key":"B80","doi-asserted-by":"publisher","first-page":"22387","DOI":"10.1074\/jbc.M113.476234","article-title":"Functional selectivity of 6\u2032-guanidinonaltrindole (6\u2032-GNTI) at kappa-opioid receptors in striatal neurons.","volume":"288","author":"Schmid","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/s0014-2999(99)00369-6","article-title":"Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor.","volume":"376","author":"Seki","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1021\/jm010095v","article-title":"Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5\u2032- to 6\u2032-position of naltrindole.","volume":"44","author":"Sharma","year":"2001","journal-title":"J. Med. Chem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bph.12692","article-title":"Pharmacology and anti-addiction effects of the novel kappa opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.","volume":"172","author":"Simonson","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.2147\/JPR.S137952","article-title":"A randomized, phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.","volume":"10","author":"Singla","year":"2017","journal-title":"J. Pain Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers.","volume":"155","author":"Soergel","year":"2014","journal-title":"Pain"},{"key":"B86","doi-asserted-by":"publisher","first-page":"10302","DOI":"10.1021\/jm301258w","article-title":"Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective kappa opioid receptor agonist.","volume":"55","author":"Spetea","year":"2012","journal-title":"J. Med. Chem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1111\/bph.13854","article-title":"Selective kappa receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice.","volume":"174","author":"Spetea","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1124\/mol.114.096503","article-title":"A novel method for analyzing extremely biased agonism at G protein-coupled receptors.","volume":"87","author":"Stahl","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jep.2013.10.059","article-title":"The effect of Salvia divinorum and Mitragyna speciosa extracts, fraction and major constituents on place aversion and place preference in rats.","volume":"151","author":"Sufka","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"B90","first-page":"259","article-title":"Antipruritic activity of the kappa-opioid receptor agonist","volume":"435","author":"Togashi","year":"2002","journal-title":"TRK-820."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/s0024-3205(01)00957-2","article-title":"The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice.","volume":"68","author":"Tsuji","year":"2001","journal-title":"Life Sci."},{"key":"B92","doi-asserted-by":"crossref","first-page":"E8178","DOI":"10.1073\/pnas.1614347113","article-title":"Distinct cortical and striatal actions of a beta-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties.","volume":"113","author":"Urs","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B93","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1124\/mol.113.088880","article-title":"Quantification of ligand bias for clinically relevant beta2-adrenergic receptor ligands: implications for drug taxonomy.","volume":"85","author":"van der Westhuizen","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.biopsych.2009.05.019","article-title":"The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake.","volume":"66","author":"van Rijn","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1021\/acschemneuro.5b00153","article-title":"Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior.","volume":"6","author":"Varadi","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1073\/pnas.0501112102","article-title":"A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.","volume":"102","author":"Waldhoer","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B97","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.alcohol.2011.10.006","article-title":"Targeting dynorphin\/kappa opioid receptor systems to treat alcohol abuse and dependence.","volume":"46","author":"Walker","year":"2012","journal-title":"Alcohol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1124\/jpet.107.132142","article-title":"2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A.","volume":"324","author":"Wang","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1124\/jpet.104.073668","article-title":"Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.","volume":"312","author":"Wang","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuropharm.2016.04.022","article-title":"kappa Opioid receptor activation in different brain regions differentially modulates anxiety-related behaviors in mice.","volume":"110","author":"Wang","year":"2016","journal-title":"Neuropharmacology"},{"key":"B101","doi-asserted-by":"publisher","first-page":"9914","DOI":"10.1073\/pnas.95.17.9914","article-title":"Morphine-activated opioid receptors elude desensitization by beta-arrestin.","volume":"95","author":"Whistler","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B102","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.","volume":"352","author":"White","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B103","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1124\/mol.113.089649","article-title":"Identification of novel functionally selective kappa-opioid receptor scaffolds.","volume":"85","author":"White","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature10939","article-title":"Structure of the human kappa-opioid receptor in complex with JDTic.","volume":"485","author":"Wu","year":"2012","journal-title":"Nature"},{"key":"B105","doi-asserted-by":"publisher","first-page":"8360","DOI":"10.1073\/pnas.122231899","article-title":"Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain.","volume":"99","author":"Xiao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B106","doi-asserted-by":"publisher","first-page":"6898","DOI":"10.1021\/bi900605n","article-title":"Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor.","volume":"48","author":"Yan","year":"2009","journal-title":"Biochemistry"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/bph.13474","article-title":"The G-protein biased partial kappa opioid receptor agonist 6\u2032-GNTI blocks hippocampal paroxysmal discharges without inducing aversion.","volume":"173","author":"Zangrandi","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00213-004-2087-0","article-title":"Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.","volume":"179","author":"Zhang","year":"2005","journal-title":"Psychopharmacology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1021\/acs.jmedchem.7b00109","article-title":"Structure-based discovery of new antagonist and biased agonist chemotypes for the kappa opioid receptor.","volume":"60","author":"Zheng","year":"2017","journal-title":"J. Med. Chem."},{"key":"B110","doi-asserted-by":"publisher","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","article-title":"Development of functionally selective, small molecule agonists at kappa opioid receptors.","volume":"288","author":"Zhou","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B111","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1007\/s11064-013-1125-x","article-title":"Decreased expression and role of GRK6 in spinal cord of rats after chronic constriction injury.","volume":"38","author":"Zhou","year":"2013","journal-title":"Neurochem. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T00:35:15Z","timestamp":1555461315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,17]]},"references-count":111,"alternative-id":["10.3389\/fphar.2019.00407"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00407","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,17]]},"article-number":"407"}}